J Korean Rheum Assoc.  2009 Jun;16(2):108-114. 10.4078/jkra.2009.16.2.108.

Prognostic Factors Affecting Survival Rate in Inflammatory Myositis

• Kim HI
• Baek HK
• Jung JK
• Jo YM
• Lee SY
• Lee SW
• Chung WT

• KMID: 2202126
• DOI: http://doi.org/10.4078/jkra.2009.16.2.108

Abstract

OBJECTIVE
To assess the 10-year cumulative survival outcome of polymyositis (PM) and dermatomyositis (DM) as well as the factors associated with the the outcome.
METHODS
Eighty five patients with PM and twenty one patients with DM were diagnosed at our university medical center between 1997 and 2007. Thirty six patients with PM and 13 patients with DM were followed up until death or until the end of January, 2008. Gender, age, AST, ALT, CPK, LDH, ESR, CRP, aldolase, drugs of therapy, combined ILD, and cancer, and duration of remission after therapy were assessed as prognostic factors of death by the Kaplan-Meier curve and Cox regression model.
RESULTS
The respective 10-year survival rate for PM and DM was 80.8% (95% confidence interval (CI): 73.3~87.2) and 55.9% (95% CI: 40.7~71.1), respectively. The median survival for PM and DM was 11.3 years (95% CI: 9.8~12.9) and 7.0 years (95% CI: 3.6~10.5), respectively. Compared to DM patients, the subjects with PM had a 167.26 fold (95% CI: 7.59~3683.19) combined ILD adjusted risk of mortality (p<0.05) and no other individual factor reached significance as a predictor of death. However, cancer had a hazard ratio (HR) of 17.00 (95% CI: 1.06~281.79) and 2.45 (95% CI: 0.78~12.45) for death in the PM and DM group, respectively.
CONCLUSION
According to an analysis of the survival and its prognostic factors in patients with PM and DM, ILD is a risk factor for mortality in PM and cancer was risk factor for mortality in both PM and DM.

Keyword

Polymyositis; Dermatomyositis; Prognostic factor

MeSH Terms

Academic Medical Centers
Dermatomyositis
Fructose-Bisphosphate Aldolase
Humans
Myositis
Polymyositis
Risk Factors
Survival Rate
Fructose-Bisphosphate Aldolase

Figure

• 

  Fig. 1. Cumulative survival curve in polymyositis.

• 

  Fig. 2. Cumulative survival curve in dermatomyositis.

Reference

References

1. Lee SH, Lim HY, Yang HI, Park SH, Cho CS, Kim HY. The clinical study on inflammatory myopathies. J Korean Rheum Assoc. 1995; 2:42–51.

2. Kim SM, Choi YH, Nam TS, Pai HJ, Oh MD, Chung MH, et al. A clinical analysis of 100 patients with dermatomyositis-polymyositis. Korean J Med. 1990; 39:6:. 812–22.

3. Choi SJ, Lee HY, Lee MH, Kim JH. A clinical analysis of 39 patients with dermatomyositis-polymyositis. Korean J Med. 1985; 29:104–11.

4. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975; 292:344–7.

5. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975; 292:403–7.

6. Rose AL, Walton JN. polymyositis: a survey of 89 cases with particular reference to treatment and prognosis. Brain. 1966; 89:747–68.

7. Medsger TA, Dawson WN, Nasi AT. The epidemiology of polymyositis. Am J Med. 1970; 48:715–23.

8. DeVere R, Bradley WG. Polymyositis: its presentation, morbidity and mortality, Brain. 1975; 98:637–66.

9. Medsger TA, Jr Robinson M, Masi AT. Factors affecting survivorship in polymyositis; a life-table study of 124 patients. Arthritis Rheun. 1971; 14:249–58.

10. Carpenter JR, Bunch TW, Engel AG. Survival in polymyositis; corticosteroids and risk factors. J Rheumatol. 1977; 4:207–14.

11. Benbassat J, Gefel D, Larholt K. Prognostic factors in polymyositis/dermatomyositis. Arthritis Rheum. 1985; 28:249–55.

12. Bohan A, Peter JB, Bowman RL, Pearson CM. A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore). 1977; 56:255–86.

13. Hochberg MC, Feldman D, Stevens MB. Adult onset polymyositis/dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a review of the literature. Semin Arthritis Rheum. 1986; 15:168–78.

14. Henrikkson KG, Sandstedt P. Polymyositis treatment and prognosis; a study of 107 patients. Acta Neurol Scand. 1982; 65:280–300.

15. Kim HS, Seo SH, Hur JA, Kwok SK, Ju JH, Yoon CH, et al. Clinical characteristics of the lung involvement in Korean patients with inflammatory myositis. J Korean Rheum Assoc. 2007; 14:15–22.

16. Veeraraghavan S, Nicholson AG, Wells AU. Lung fibrosis: new classifications and therapy. Curr Opin Rheumatol. 2001; 13:500–4.

17. Selva-O'Callaghan A, Labrador-Horrillo M, Munoz-Gall X, Martinez-Gomez X, Majo-Masferrer J, Solans-Laque R, et al. Polymyositis/dermatomyositis-associated lung disease: analysis of a series of 81 patients. Lupus. 2005; 14:534–42.

18. Barnes BE. Dermatomyositis and malignancy; a review of the literature. Ann Intern Med. 1976; 84:68–76.

19. Fathi M, Dastmalchi M, Rasmussen E, Lundberg IE, Tornling G. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis. 2004; 63:297–301.

20. Tomoyuki F, Takafumi S, Yutaro N, Noriyuki E, Kyo-taro I, Mikio T, et al. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J Rheumatol. 2005; 32:58–64.

21. Primack SL, Muller NL. Radiologic manifestations of the systemic autoimmune diseases. Clin Chest Med. 1998; 19:573–86.

22. Ogilvie CM, Forster RE, Blakemore WS, Morton JW. A standardized breathholding technique for clinical measurement of the diffusing capacity of the lung for carbon monoxide. J Clin Invest. 1957; 36:1–7.

23. Schnabel A, Reuter M, Biederer J, Richter C, Gross WL. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum. 2003; 32:273–84.

24. Chae JD, Oh HB, Lee CG, Yoo B, Sohn MJ, Yoo SB. Detection of antoantibodies for extractable nuclear antigens by LG immunoblot kit. Korean J Clin Pathol. 2002; 22:34–41.

25. Hochberg MC, Feldman D, Steven MB. Antibody to Jo-1 in polymyositis/dermatomyositis: association with interstitial pulmonary disease. J Rheumatol. 1984; 11:663–5.

26. Yoshida S, Akinzuki M, Mimori T. The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue disease: a marker for a subset of polymyositis with interstitial pulmonary fibrosis, Arthritis Rheum. 1983; 26:604–11.

27. Koh ET, Seow A, Ong B, Ratnagopal P, Tija H, Chng HH. Adult onset polymyositis/dermatositis: clinical and laboratory features and treatment response in 75 patients. Ann Rheum Dis. 1993; 52:857–61.

28. Choy EH, Isenberg DA. Treatment of dermatomyositis and polymyositis. Rheumatology Oxford. 2002; 41:7–13.

29. Amato AA, Griggs RC. Treatment of idiopathic inflammatory myopathies. Curr Opin Neurol. 2003; 16:569–75.

30. Grogan PM, Katz JS. Inflammatory myopathies. Curr Treat Options Neurol. 2004; 6:155–61.